Oppenheimer Asset Management Inc. Has $1.75 Million Stake in argenx SE (NASDAQ:ARGX)

Oppenheimer Asset Management Inc. reduced its position in argenx SE (NASDAQ:ARGX) by 1.1% in the 3rd quarter, Holdings Channel reports. The firm owned 3,220 shares of the company’s stock after selling 35 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in argenx were worth $1,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares during the period. J.Safra Asset Management Corp boosted its holdings in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of argenx in the 2nd quarter worth approximately $76,000. Finally, Cromwell Holdings LLC grew its holdings in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Trading Down 5.2 %

NASDAQ:ARGX opened at $564.22 on Monday. argenx SE has a 1 year low of $327.73 and a 1 year high of $611.22. The stock has a 50-day moving average price of $552.89 and a two-hundred day moving average price of $482.65. The stock has a market cap of $33.74 billion, a price-to-earnings ratio of -641.16 and a beta of 0.61.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the previous year, the firm earned ($1.25) EPS. Sell-side analysts forecast that argenx SE will post 2.2 earnings per share for the current year.

Wall Street Analyst Weigh In

ARGX has been the subject of several research reports. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and raised their price objective for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Oppenheimer raised their price target on shares of argenx from $560.00 to $646.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective on the stock in a report on Tuesday, November 12th. Wells Fargo & Company lifted their target price on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Finally, Wedbush upped their price target on argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.79.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.